Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $18.59 in the last session, up 0.16% from day before closing price of $18.56. In other words, the price has increased by $0.16 from its previous closing price. On the day, 3.17 million shares were traded. AVDL stock price reached its highest trading level at $18.62 during the session, while it also had its lowest trading level at $18.55.
Ratios:
We take a closer look at AVDL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 306.47. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $16.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1810728448 and an Enterprise Value of 1761541120. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.17 while its Price-to-Book (P/B) ratio in mrq is 19.83. Its current Enterprise Value per Revenue stands at 7.968 whereas that against EBITDA is 4948.149.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.48, which has changed by 0.4376452 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $18.65, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 20.02%, while the 200-Day Moving Average is calculated to be 74.19%.
Shares Statistics:
According to the various share statistics, AVDL traded on average about 2.33M shares per day over the past 3-months and 7522400 shares per day over the past 10 days. A total of 96.78M shares are outstanding, with a floating share count of 92.75M. Insiders hold about 4.48% of the company’s shares, while institutions hold 82.40% stake in the company. Shares short for AVDL as of 1760486400 were 9982108 with a Short Ratio of 4.28, compared to 1757894400 on 10444932. Therefore, it implies a Short% of Shares Outstanding of 9982108 and a Short% of Float of 12.0.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate. The current performance of Avadel Pharmaceuticals plc (AVDL) in the stock market.The consensus estimate for the next quarter is $0.09, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.34 and -$0.03 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.76, with 7.0 analysts recommending between $1.14 and $0.49.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $73.58M. It ranges from a high estimate of $74.7M to a low estimate of $72.52M. As of. The current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 10 analysts are estimating revenue of $78.05M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $73.85M.
A total of 10 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $267.02M, resulting in an average revenue estimate of $272.27M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $356.12M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
